Publicaciones en colaboración con investigadores/as de Hospital Virgen del Camino (15)

2022

  1. Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)

    Journal of Clinical Medicine

  2. Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCU

    Journal of Crohn's & colitis, Vol. 16, Núm. 7, pp. 1049-1058

  3. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

    Journal of Clinical Medicine, Vol. 11, Núm. 2

  4. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

    Journal of Clinical Medicine, Vol. 11, Núm. 24

2021

  1. Incidence, clinical characteristics and management of inflammatory bowel disease in spain: Large-scale epidemiological study

    Journal of Clinical Medicine, Vol. 10, Núm. 13

2019

  1. EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain

    Therapeutic Advances in Gastroenterology, Vol. 12

2018

  1. Adalimumab treatment of anti-TNF-naïve patients with ulcerative colitis: Deep remission and response factors

    Digestive and Liver Disease, Vol. 50, Núm. 8, pp. 812-819

  2. Serial tuberculin skin tests improve the detection of latent tuberculosis infection in patients with inflammatory bowel disease

    Journal of Crohn's and Colitis, Vol. 12, Núm. 11, pp. 1270-1279

2017

  1. Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis

    Inflammatory Bowel Diseases, Vol. 23, Núm. 8, pp. 1394-1402

  2. Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients

    Journal of Gastroenterology, Vol. 52, Núm. 7, pp. 788-799

  3. Erratum to: Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients (J Gastroenterol, 10.1007/s00535-016-1274-1)

    Journal of Gastroenterology

2016

  1. Previous exposure to biologics and C-reactive protein are associated with the response to tacrolimus in inflammatory bowel disease

    Revista Espanola de Enfermedades Digestivas, Vol. 108, Núm. 9, pp. 550-557

2012

  1. Partially covered self-expanding metal stent for unresectable malignant extrahepatic biliary obstruction: Results of a large prospective series

    Surgical Endoscopy, Vol. 26, Núm. 1, pp. 222-229

2011

  1. Clinical patterns and outcomes of ischaemic colitis: Results of the Working Group for the Study of Ischaemic Colitis in Spain (CIE study)

    Scandinavian Journal of Gastroenterology, Vol. 46, Núm. 2, pp. 236-246

2006

  1. Consensus document on the use of granulocytapheresis in patients with inflammatory bowel disease

    Gastroenterologia y Hepatologia, Vol. 29, Núm. 2, pp. 85-92